Short answer
Evolent Health, Inc. (EVH) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $480M (down 22.8% year over year) with net income of −$21M.
Q3 2025 key financials · XBRL
- Revenue
- $480M
- −22.8% YoY · +7.9% QoQ
- Net income
- −$21M
- +9.8% YoY · −4.9% QoQ
- Operating margin
- 0.2%
- EPS (diluted)
- −$0.24
- +11.1% YoY · +45.5% QoQ
Source: XBRL data from the Evolent Health, Inc. (EVH) Q3 2025 10-Q on SEC EDGAR. USD.
Evolent Health, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- MD&A excerpt contains no quarterly revenue, year-over-year, profitability, or segment results
Risk Factors
- New 2031 Notes issuance triggered conversion risk, potentially requiring cash settlement and reducing liquidity
- $1,085.0 million debt outstanding as of September 30, 2025, constraining cash available for growth and acquisitions
- OBBBA healthcare changes could reduce Medicaid, Medicare, and ACA enrollment and materially affect results
- Medicare Advantage market terminations and declining enrollment threaten partner-linked revenue through 2026
- Floating-rate SOFR exposure could significantly increase debt-service obligations if interest rates rise further
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Evolent Health, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.